Clinical trial
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of…
NCT00193193 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193193 |
|---|---|
| Title | Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma |
| Official title | A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, Estramustine, Carboplatin |
| Enrollment | 100 |
| Start date | Aug 1, 2000 |
| Primary completion | Dec 1, 2003 |
| Completion | Feb 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 4, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: